C
CTMX
Cytomx Therapeutics Inc
2.750
-0.030-1.08%After Hours: 2.740 -0.010 -0.37%19:46 09/24 EDT
OPEN/PREV CLOSE2.610/2.580
TODAY RANGE2.505-2.630
VOL1.12M
MARKET CAP561.09M
52 WEEK RANGE2.480-8.21
AVG VOL (3M)3.37M
% TURNOVER0.51%
TURNOVER--
P/E (TTM)-5.6296
% RANGE4.85%
EPS(TTM)-0.4574
P/E(FORWARD)-6.3934
P/B1.857
BVPS1.386
DIVIDEND--
P/S5.75
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP530.78M
SHARES OUTSTANDING217.90M
NEXT EARNINGS11/04-11/09
FREE FLOAT206.13M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·09/23 12:20
Analysts’ Top Healthcare Picks: AbbVie (ABBV), CytomX Therapeutics (CTMX)
Seeking Alpha·08/27 15:34
CytomX gains Fast Track status for colorectal cancer antibody-drug conjugate
TipRanks·08/27 12:10
CytomX Therapeutics gets Fast Track Designation for Varseta-M
TipRanks·08/17 12:28
CytomX Therapeutics (CTMX) Gets a Buy from J.P. Morgan
TipRanks·08/17 07:58
CytomX Therapeutics price target lowered to $11 from $12 at JPMorgan
Dow Jones·08/13 15:35
CytomX Therapeutics Price Target Cut to $11.00/Share From $12.00 by JP Morgan
Dow Jones·08/13 15:35
CytomX Therapeutics Is Maintained at Overweight by JP Morgan
Seeking Alpha·08/12 20:24
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
Dow Jones·08/10 14:22
CytomX Therapeutics Price Target Cut to $14.00/Share From $15.00 by Guggenheim
Dow Jones·08/10 14:22
CytomX Therapeutics Is Maintained at Buy by Guggenheim
Benzinga·08/10 14:13
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
TipRanks·08/10 11:35
CytomX Therapeutics price target lowered to $14 from $15 at Guggenheim
Same Industry
Name/Symbol
Change%
Price